In a massive deal that is one of the year’s biggest, Akeso Inc. signed a collaboration and license deal with Summit Therapeutics Inc. to out-license its bispecific antibody, ivonescimab (AK-112), for development and commercialization in the U.S., Canada, Europe and Japan. Read More
Gossamer Bio Inc. shares (NASDAQ:GOSS) fell 74.6% to $2.36 Dec. 6 after the disclosure of phase II results that, while meeting the study's primary endpoint of reducing pulmonary vascular resistance vs. placebo, failed to show the company's pulmonary arterial hypertension (PAH) candidate, seralutinib, holding its own against the performance of Merck & Co. Inc.'s PAH candidate, sotatercept, in separate PAH studies. Read More
Vega Therapeutics Inc. emerged from stealth in advance of a podium presentation at this year’s American Society of Hematology meeting in New Orleans. The company, a spin-out from Star Therapeutics Inc., will disclose preclinical data on its lead drug candidate VGA-039, a first-in-class antibody in development for von Willebrand disease. Read More
Biopharma financings are tracking only 3% below 2019’s full-year total, but the volume of activity is at its lowest point since 2017. With a total of $56.1 billion raised, 2022 is currently the sixth best financing year on record, but it is significantly behind some of the years that rank higher. Read More
Accession Therapeutics Ltd. has raised £16.6 million (US$20.3 million) in a series A round, as it prepares to take two targeted oncolytic/payload combination viruses into the clinic. At the same time, the company disclosed that the scientist who devised the tumor-only targeting mechanism is Alan Parker, professor of translational virotherapies at Cardiff University. Read More
We wrapped up 2022 and are preparing for 2023 on this BioWorld Insider podcast. Staff writer Lee Landenberger talked to four CEOs, visionaries of companies producing new science and drug development. The CEOs offered their insights into what happened this year and looked at the challenges and opportunities for next year. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcutis, Bioage, Denali, Ellipses, First Wave, Hepion, Hillevax, Innovent, Longboard, Lynk, Neurona, Nkarta, Novartis, Qilu, Stoke, Syndax, Urogen, Valneva, Zynerba. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascendis, Biogen, Hexaell, Ideaya, Idorsia, Pfizer, Protalix, Redhill, Syndax. Read More
